Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 3, 2007, Pages 1219-1227

  López, Mercedes N ^a,b   Pereda, Cristian ^a   Ramírez, Marcos ^a   Mendoza Naranjo, Ariadna ^a   Serrano, Antonio ^a   Ferreira, Arturo ^a   Poblete, Rodrigo ^c   Kalergis, Alexis M ^d   Kiessling, Rolf ^e   Salazar Onfray, Flavio ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^c HOSPITAL DEL SALVADOR   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e Karolinska Krankenhaus   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; INTERLEUKIN 10; INTERLEUKIN 4; MELAN A; MELANOCORTIN 1 RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MP1.1B7; MONOCLONAL ANTIBODY MP1.1C11; PROTEIN S 100; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ALPHA INTERMEDIN; MART1 ANTIGEN; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; TUMOR ANTIGEN; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER TISSUE; CONTROLLED STUDY; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SURFACE PROPERTY; UVEA MELANOMA; CELL CULTURE; ENZYME IMMUNOASSAY; IMMUNOTHERAPY; MELANOMA; METABOLISM; UVEA TUMOR; WESTERN BLOTTING;

ALPHA-MSH; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; RECEPTOR, MELANOCORTIN, TYPE 1; S100 PROTEINS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 34047246838     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0090     Document Type: Article

References (39)

1. Stang A, Parkin DM, Ferlay J, Jockei KH. International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification. Int J Cancer. 2005;114:114-1123.
2. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:962-965.
3. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005;18:75-84.
4. Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000;7:1561-1568.
5. Ardavin C, Amigorena S, Reis e Sousa C. Dendritic cells: immunobiology and cancer immunotherapy. Immunity. 2004;20:17-23.
6. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
7. Escobar A, Lopez M, Serrano A, et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol. 2005;142:555-568.
8. Shields JA, Mashayekhi A, Ra S, Shields CL. Pseudomelanomas of the posterior uveal tract: the 2006 Taylor R. Smith Lecture. Retina. 2005;25:767-771.
9. Keijser S, Missotten GS, Bonfrer JM, de Wolff-Rouendaal D, Jager MJ, de Keizer RJ. Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions. Br J Ophthalmol. 2006;90:213-217.
10. Iwamoto S, Burrows RC, Kalina RE, et al. Immunophenotypic differences between uveal and cutaneous melanomas. Arch Ophthalmol. 2002;120:466-470.
11. Heegaard S, Jensen OA, Prause JU. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45. Melanoma Res. 2000;10:350-354.
12. Luyten GP, van der Spek CW, Brand I, et al. Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines. Melanoma Res. 1998;8:11-16.
13. Stefansson K, Wollmann R, Jerkovic M. S-100 protein in soft-tissue tumors derived from Schwann cells and melanocytes. Am J Pathol. 1982;106:261-268.
14. Adema GJ, de Boer AJ, van't Hullenaar R, et al. Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol. 1993;143:1579-1585.
15. Salazar-Onfray F, Lopez M, Lundqvist A, et al. Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer.2002 12;87:414-422.
16. Siegrist W, Solca F, Stutz S, et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 1989;49:6352-6358.
17. Farooqui JZ, Medrano EE, Boissy RE, Tigelaar RE, Nordlund JJ. Thy-1+ dendritic cells express truncated form of POMC mRNA. Exp Dermatol. 95;4:297-301.
18. Star RA, Rajora N, Huang J, Stock RC, Catania A, Lipton JM. Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte- stimulating hormone. Proc Natl Acad Sci USA. 1995;92:8016-8020.
19. Schwahn DJ, Xu W, Herrin AB, Bales ES, Medrano EE. Tyrosine levels regulate the melanogenic response to alpha-melanocyte-stimulating hormone in human melanocytes: implications for pigmentation and proliferation. Pigment Cell Res. 2001;14:32-39.
20. Chhajlani V, Wikberg JE. Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA. FEBS Lett. 1992;309:417-420.
21. Gantz I, Miwa H, Konda Y, et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem. 1993;268:15174-15179.
22. Xia Y, Muceniece R, Wikberg JE. Immunological localisation of melanocortin 1 receptor on the cell surface of WM266 - 4 human melanoma cells. Cancer Lett. 1996;98:157-162.
23. Curry JL, Pinto W, Nickoloff BJ, Slominski AT. Human keratinocytes express functional alpha-MSH (MC1-R) receptors. In Vitro Cell Dev Biol Anim. 2001;37:234-236.
24. Thornwall M, Dimitriou A, Xu X, Larsson E, Chhajlani V. Immunohistochemical detection of the melanocortin 1 receptor in human testis, ovary and placenta using specific monoclonal antibody. Horm Res. 1997;48:215-218.
25. Salazar-Onfray F, Nakazawa T, Chhajlani V, et al. Synthetic peptides derived from the melanocyte stimulating hormone receptor MC1R can stimulate HLA-A2 restricted CTL that recognize naturally processed peptides on human melanoma cells. Cancer Res. 1997;57:4348-4355.
26. Bhardwaj R, Becher E, Mahnke K, et al. Evidence for the differential expression of functional α-melanocyte-stimulating hormone receptor MC-1 on human monocytes. J Immunol. 1997;158:3378-3384.
27. Hurks HM, Metzelaar-Blok JA, Mulder A, Claas FH, Jager MJ. High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines. Int J Cancer. 2000;85:697-702.
28. Luger TA, Brzoska T, Scholzen TE, et al. The role of alpha-MSH as modulator of cutaneous inflammation. Ann NY Acad Sci. 2000;917:232-238.
29. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56:1-29.
30. Govindan SV, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies. Technol Cancer Res Treat. 2005;4:375-392.
31. Huston JS, George AJ. Engineered antibodies take center stage. Hum Antibodies. 2001;10:127-142.
32. Baselga J, Mendelsohn J. Type I receptor tyrosine kinases as targets for therapy in breast cancer. J Mammary Gland Biol Neoplasia. 1997;2:165-174.
33. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
34. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood. 2003;101:391-398.
35. Margolin K, Gordon MS, Holmgren E, et al. Phase IB trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacological and long-term safety data. J Clin Oncol. 2001;19:851-856.
36. Hanai N, Nakamura K, Shitara K. Recombinant antibodies against ganglioside expressed on tumor cells. Cancer Chemother Pharmacol. 2000;46:13-17.
37. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749-795.
38. Marciano BE, Wesley R, De Carlo ES, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis. 2004;39:692-699.
39. Key LL Jr, Rodriguiz RM, Willi SM, et al. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med. 1995;332:1594-1599.